Organovo Holdings, Inc. is working together with researchers at Autodesk, Inc., to create the first 3D design software for bioprinting.
The software, which will be used to control Organovo’s NovoGen MMX bioprinter, will represent a major step forward in usability and functionality for designing three-dimensional human tissues, and has the potential to open up bioprinting to a broader group of users.
Organovo’s 3D bioprinting technology is used to create living human tissues that are three-dimensional, architecturally correct, and made entirely of living human cells, without requiring a synthetic extra-cellular matrix. The resulting structures can function like native human tissues, and represent an opportunity for advancement in medical research, drug discovery and development, and, in the future, surgical therapies and transplantation.
Organovo Holdings, Inc.